The advance of institutional opening-up can help unlock dividends from institutional innovation and attract high-end global ...
The Chosun Ilbo on MSN
Novo Nordisk's oral obesity drug approval intensifies market war
The era of "oral obesity medications" has officially begun as Danish pharmaceutical company Novo Nordisk’s obesity treatment received U.S. Food and Drug Administration (FDA) approval in pill form.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback